US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6924264B1
(en)
*
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001266557A1
(en)
*
|
2000-04-12 |
2001-10-23 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
ATE424413T1
(en)
*
|
2000-06-16 |
2009-03-15 |
Lilly Co Eli |
ANALOGUE OF GLUCAGONE-LIKE PEPTIDE-1
|
JP4280803B2
(en)
|
2000-12-08 |
2009-06-17 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Chronic lymphocytic leukemia cell line and its use for producing antibodies
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
AU2002228608A1
(en)
*
|
2000-12-13 |
2002-06-24 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
DE60228972D1
(en)
*
|
2001-07-31 |
2008-10-30 |
Us Gov Health & Human Serv |
GLP 1 EXENDIN 4 PEPTIDE ANALOG AND THEIR USES
|
EP1432730A4
(en)
*
|
2001-08-23 |
2006-10-11 |
Lilly Co Eli |
Glucagon-like peptide-1 analogs
|
US7176278B2
(en)
*
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
IL160917A0
(en)
*
|
2001-10-18 |
2004-08-31 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2261250B1
(en)
|
2001-12-21 |
2015-07-01 |
Human Genome Sciences, Inc. |
GCSF-Albumin fusion proteins
|
US20080194481A1
(en)
*
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
WO2003058203A2
(en)
*
|
2002-01-08 |
2003-07-17 |
Eli Lilly And Company |
Extended glucagon-like peptide-1 analogs
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
EP1532261B1
(en)
*
|
2002-05-24 |
2010-02-10 |
Medtronic, Inc. |
Methods and dna constructs for high yield production of polypeptides
|
WO2004002417A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Centocor, Inc. |
Mammalian ch1 deleted mimetibodies, compositions, methods and uses
|
US9321832B2
(en)
|
2002-06-28 |
2016-04-26 |
Domantis Limited |
Ligand
|
CN102268094A
(en)
*
|
2002-08-30 |
2011-12-07 |
比奥雷克西斯药物公司 |
Modified transferrin fusion proteins
|
EP1569682A2
(en)
*
|
2002-12-03 |
2005-09-07 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
EP1688148A1
(en)
*
|
2002-12-03 |
2006-08-09 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
US7655618B2
(en)
|
2002-12-27 |
2010-02-02 |
Diobex, Inc. |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
KR20050086948A
(en)
|
2002-12-27 |
2005-08-30 |
디오벡스, 인코포레이티드 |
Compositions and methods for the prevention and control of insulin-induced hypoglycemia
|
AU2003292685A1
(en)
*
|
2003-01-10 |
2004-08-10 |
Niigata Tlo Corporation |
Vector for gene therapy and method of quantifying target protein in mammal or cultured cells with the administration of the vector for gene theraphy
|
WO2004069862A1
(en)
*
|
2003-02-06 |
2004-08-19 |
Keio University |
Peptide conjugate
|
PT1605897E
(en)
*
|
2003-03-19 |
2012-09-10 |
Lilly Co Eli |
Polyethelene glycol link glp-1 compounds
|
BRPI0408978B8
(en)
|
2003-04-08 |
2021-07-27 |
Novo Nordisk As |
processes for regenerating a chromatographic stationary phase
|
WO2004089985A1
(en)
*
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
WO2004103390A2
(en)
|
2003-05-15 |
2004-12-02 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
KR100758755B1
(en)
|
2003-06-12 |
2007-09-14 |
일라이 릴리 앤드 캄파니 |
-1 glp-1 analog fusion proteins
|
DE602004011770T2
(en)
*
|
2003-06-12 |
2009-02-05 |
Eli Lilly And Co., Indianapolis |
FUSION PROTEIN
|
TW200526254A
(en)
*
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
WO2005028516A2
(en)
|
2003-09-19 |
2005-03-31 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
JP4870569B2
(en)
|
2003-11-13 |
2012-02-08 |
ハンミ ホールディングス カンパニー リミテッド |
Protein conjugate using immunoglobulin fragment and method for producing the same
|
KR101135244B1
(en)
*
|
2007-11-29 |
2012-04-24 |
한미사이언스 주식회사 |
A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
US20090238838A1
(en)
*
|
2003-11-13 |
2009-09-24 |
Hanmi Pharm. Ind. Co. Ltd. |
Insulinotropic peptide conjugate using an immunoglobulin fc
|
US8263084B2
(en)
*
|
2003-11-13 |
2012-09-11 |
Hanmi Science Co., Ltd |
Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
|
CA2545034C
(en)
|
2003-11-20 |
2013-03-05 |
Novo Nordisk A/S |
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
|
JP4865565B2
(en)
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Controlling food selection using GLP-1 agonists
|
CN101665538A
(en)
*
|
2003-12-18 |
2010-03-10 |
诺沃挪第克公司 |
Novel GLP-1 analogues linked to albumin-like agents
|
US20060252693A1
(en)
*
|
2004-01-29 |
2006-11-09 |
Wolfgang Glaesner |
Glucagon-like peptide-1 analogs
|
CN1980687B
(en)
*
|
2004-02-09 |
2015-05-13 |
人类基因科学公司 |
Albumin fusion proteins
|
HUE027902T2
(en)
*
|
2004-02-09 |
2016-11-28 |
Human Genome Sciences Inc Corp Service Company |
Albumin fusion proteins
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
BRPI0507594A
(en)
*
|
2004-02-11 |
2007-07-03 |
Amylin Pharmaceuticals Inc |
hybrid polypeptides with selectable properties
|
EP1789440A4
(en)
|
2004-02-11 |
2008-03-12 |
Amylin Pharmaceuticals Inc |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
AU2005231359A1
(en)
*
|
2004-03-31 |
2005-10-20 |
Centocor, Inc. |
Human GLP-1 mimetibodies, compositions, methods and uses
|
HUE039448T2
(en)
|
2004-04-21 |
2018-12-28 |
Alexion Pharma Inc |
Bone delivery conjugates and method of using same to target proteins to bone
|
SI1751184T1
(en)
|
2004-05-13 |
2010-01-29 |
Lilly Co Eli |
Fgf-21 fusion proteins
|
EP2316446A1
(en)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
JP2008515856A
(en)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
Delayed GLP-1 compound
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
KR20070094909A
(en)
*
|
2004-12-02 |
2007-09-27 |
도만티스 리미티드 |
Bispecific domain ant1bodies targeting serum albumin and glp-1 or pyy
|
WO2006068910A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Eli Lilly And Company |
Glp-1 analog fusion protein formulations
|
JP2008525477A
(en)
*
|
2004-12-22 |
2008-07-17 |
セントカー・インコーポレーテツド |
GLP-1 agonists, compositions, methods and uses
|
WO2007022123A2
(en)
*
|
2005-08-11 |
2007-02-22 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
US20090016959A1
(en)
*
|
2005-02-18 |
2009-01-15 |
Richard Beliveau |
Delivery of antibodies to the central nervous system
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
CN101128214A
(en)
*
|
2005-03-18 |
2008-02-20 |
诺和诺德公司 |
Extended GLP-1 compounds
|
MX2007011975A
(en)
*
|
2005-03-28 |
2008-03-14 |
Johnson & Johnson |
Human glp-1 mimetibodies, compositions, methods and uses.
|
LT2650020T
(en)
*
|
2005-05-06 |
2016-12-12 |
Providence Health & Services - Oregon |
Trimeric OX40-immunoglobulin fusion protein and methods of use
|
US8183340B2
(en)
*
|
2005-05-13 |
2012-05-22 |
Eli Lilly And Company |
GLP-1 pegylated compounds
|
WO2007012188A1
(en)
*
|
2005-07-27 |
2007-02-01 |
Qinghua Wang |
GLP/1/EXENDM 4 IgG Fc FUSION CONSTRUCTS FOR TREATMENT OF DIABETES
|
CA2616551A1
(en)
*
|
2005-07-29 |
2007-02-15 |
Amprotein Corporation |
Chimeric therapeutic agents
|
WO2007016764A1
(en)
*
|
2005-08-06 |
2007-02-15 |
Qinghua Wang |
Composition and method for prevention and treatment of type i diabetes
|
JP2009504681A
(en)
*
|
2005-08-11 |
2009-02-05 |
アミリン・ファーマシューティカルズ,インコーポレイテッド |
Hybrid polypeptides with selectable properties
|
ES2336575T3
(en)
*
|
2005-09-22 |
2010-04-14 |
Biocompatibles Uk Limited |
GLP-1 FUSION POLYPEPTIDES (PEPTIDE-1 SIMILAR TO GLUCAGON) WITH INCREASED RESISTANCE TO PEPTIDASE.
|
US20090286724A1
(en)
*
|
2005-10-26 |
2009-11-19 |
Chugai Seiyaku Kabushiki Kaisha |
Aggregable glp-1 analogue and sustained-release pharmaceutical composition
|
HUE029798T2
(en)
*
|
2005-11-04 |
2017-03-28 |
Glaxosmithkline Llc |
Methods for administering hypoglycemic agents
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
CN1962695B
(en)
*
|
2005-11-09 |
2011-08-31 |
浙江德清安平生物制药有限公司 |
GLP-1 infusion proteins, their preparation and use
|
US20080280328A1
(en)
*
|
2005-11-18 |
2008-11-13 |
Novozymes A/S |
Glucoamylase Variants
|
WO2007063907A1
(en)
*
|
2005-11-30 |
2007-06-07 |
Shionogi & Co., Ltd. |
Sugar chain adduct of peptide and pharmaceutical comprising the same as active ingredient
|
US8293869B2
(en)
|
2005-12-16 |
2012-10-23 |
Nektar Therapeutics |
Polymer conjugates of GLP-1
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
CA2634034A1
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
DK2463305T3
(en)
|
2006-01-12 |
2016-08-29 |
Alexion Pharma Inc |
Antibodies to OX-2 / CD200 and uses thereof
|
US20150038413A1
(en)
|
2006-02-03 |
2015-02-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US7553941B2
(en)
*
|
2006-02-03 |
2009-06-30 |
Modigene Inc |
Long-acting polypeptides and methods of producing same
|
US20140113860A1
(en)
|
2006-02-03 |
2014-04-24 |
Prolor Biotech Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US9249407B2
(en)
|
2006-02-03 |
2016-02-02 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
US8946155B2
(en)
|
2006-02-03 |
2015-02-03 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US8450269B2
(en)
|
2006-02-03 |
2013-05-28 |
Prolor Biotech Ltd. |
Long-acting growth hormone and methods of producing same
|
US8048849B2
(en)
|
2006-02-03 |
2011-11-01 |
Modigene, Inc. |
Long-acting polypeptides and methods of producing same
|
US8759292B2
(en)
|
2006-02-03 |
2014-06-24 |
Prolor Biotech, Llc |
Long-acting coagulation factors and methods of producing same
|
US8476234B2
(en)
*
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
US10221228B2
(en)
|
2006-02-03 |
2019-03-05 |
Opko Biologics Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
US10351615B2
(en)
|
2006-02-03 |
2019-07-16 |
Opko Biologics Ltd. |
Methods of treatment with long-acting growth hormone
|
US9458444B2
(en)
|
2006-02-03 |
2016-10-04 |
Opko Biologics Ltd. |
Long-acting coagulation factors and methods of producing same
|
EP1816201A1
(en)
*
|
2006-02-06 |
2007-08-08 |
CSL Behring GmbH |
Modified coagulation factor VIIa with extended half-life
|
CN101003574B
(en)
*
|
2006-02-21 |
2010-12-15 |
大连帝恩生物工程有限公司 |
Recombined expression of peptide for lowering blood sugar in long acting, and application in medication for treating diabetes
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
DE602006009631D1
(en)
|
2006-05-10 |
2009-11-19 |
Biocompatibles Uk Ltd |
Spherical microcapsules containing GLP-1 peptides, their production and their use
|
MX2008015107A
(en)
|
2006-05-26 |
2008-12-09 |
Amylin Pharmaceuticals Inc |
Composition and methods for treatment of congestive heart failure.
|
EP2474318A1
(en)
|
2006-06-07 |
2012-07-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AR061930A1
(en)
|
2006-07-18 |
2008-10-01 |
Centocor Inc |
MIMETICBODIES OF GLP-1 HUMANS, COMPOSITIONS, METHODS AND USES
|
AU2007278994B2
(en)
|
2006-07-24 |
2013-08-15 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
CL2007002502A1
(en)
|
2006-08-31 |
2008-05-30 |
Hoffmann La Roche |
VARIANTS OF THE SIMILAR GROWTH FACTOR TO HUMAN INSULIN-1 (IGF-1) PEGILATED IN LISIN; METHOD OF PRODUCTION; FUSION PROTEIN THAT UNDERSTANDS IT; AND ITS USE TO TREAT ALZHEIMER'S DISEASE.
|
JP4958975B2
(en)
*
|
2006-08-31 |
2012-06-20 |
エフ.ホフマン−ラ ロシュ アーゲー |
Method for producing insulin-like growth factor I
|
US20110039776A1
(en)
*
|
2006-09-06 |
2011-02-17 |
Ashutosh Chilkoti |
Fusion peptide therapeutic compositions
|
TWI430806B
(en)
*
|
2006-09-13 |
2014-03-21 |
Smithkline Beecham Corp |
Methods for administering long-lasting hypoglycemic agents
|
TWI428346B
(en)
*
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
JP2008169195A
(en)
|
2007-01-05 |
2008-07-24 |
Hanmi Pharmaceutical Co Ltd |
Insulinotopic peptide drug combo using carrier material
|
AU2011254001B2
(en)
*
|
2007-01-05 |
2012-08-02 |
Covx Technologies Ireland Limited |
Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
EP1972349A1
(en)
*
|
2007-03-21 |
2008-09-24 |
Biocompatibles UK Limited |
GLP-1 fusion peptides conjugated to polymer(s), their production and use
|
EP1975176A1
(en)
*
|
2007-03-27 |
2008-10-01 |
Biocompatibles UK Limited |
Novel glp-1 fusion peptides, their production and use
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
AU2008244523B2
(en)
|
2007-04-23 |
2012-02-16 |
Intarcia Therapeutics, Inc. |
Suspension formulations of insulinotropic peptides and uses thereof
|
JP2009019027A
(en)
*
|
2007-07-16 |
2009-01-29 |
Hanmi Pharmaceutical Co Ltd |
Insulin secretion peptide derivative in which amino acid of amino terminal is varied
|
KR20100036362A
(en)
|
2007-07-25 |
2010-04-07 |
알렉시온 파마슈티칼스, 인코포레이티드 |
Methods and compositions for treating autoimmune disease
|
EP3260129A1
(en)
|
2007-08-03 |
2017-12-27 |
Eli Lilly and Company |
An fgf-21 compound and a glp-1 compound for use in the treatment of obesity
|
WO2009030774A1
(en)
*
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Truncated glp-1 derivatives and their therapeutical use
|
CN101842109B
(en)
|
2007-09-05 |
2014-01-29 |
诺沃-诺迪斯克有限公司 |
Peptides derivatized with A-B-C-D- and their therapeutical use
|
US8895694B2
(en)
|
2007-09-05 |
2014-11-25 |
Novo Nordisk A/S |
Glucagon-Like Peptide-1 derivatives and their pharmaceutical use
|
MX2010003099A
(en)
|
2007-09-21 |
2010-05-17 |
Univ California |
Targeted interferon demonstrates potent apoptotic and anti-tumor activities.
|
EP2214700A4
(en)
*
|
2007-11-02 |
2012-08-22 |
Janssen Biotech Inc |
Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
|
SG189682A1
(en)
*
|
2008-03-31 |
2013-05-31 |
Glaxo Group Ltd |
Drug fusions and conjugates
|
WO2009121551A1
(en)
*
|
2008-04-03 |
2009-10-08 |
F. Hoffmann-La Roche Ag |
Pegylated insulin-like-growth-factor assay
|
CN101328221B
(en)
*
|
2008-04-14 |
2011-03-23 |
中国药科大学 |
Hypoglycemic polypeptide fused protein, structure and use of derivate thereof
|
EP2926825A1
(en)
|
2008-06-27 |
2015-10-07 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
WO2010011096A2
(en)
|
2008-07-23 |
2010-01-28 |
Hanmi Pharmaceutical Co., Ltd. |
A polypeptide complex comprising non-peptidyl polymer having three functional ends
|
RU2526804C2
(en)
|
2008-08-06 |
2014-08-27 |
Ново Нордиск Хелс Кеа Аг |
Conjugated proteins with prolonged action in vivo
|
US20100075897A1
(en)
*
|
2008-09-23 |
2010-03-25 |
Jinan University |
Method for sustainedly releasing bioactive peptides and application thereof
|
MX2011004017A
(en)
|
2008-10-15 |
2011-06-24 |
Angiochem Inc |
Conjugates of glp-1 agonists and uses thereof.
|
CN102307897B
(en)
|
2008-12-05 |
2016-01-20 |
葛兰素集团有限公司 |
Select the method for protease resistant polypeptide
|
CA2745524C
(en)
|
2008-12-05 |
2020-06-09 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
PL2373681T3
(en)
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Pharmaceutical compositions of albiglutide
|
RU2539797C2
(en)
|
2009-01-22 |
2015-01-27 |
Ново Нордиск Хелс Кеа Аг |
Human growth hormone derivative highly resistant to proteolytic degradation, method for preparing this derivative, using it, method of treating, and pharmaceutical composition
|
SG2014012918A
(en)
|
2009-02-11 |
2014-04-28 |
Novozymes Biopharma Dk As |
Albumin variants and conjugates
|
US9238878B2
(en)
|
2009-02-17 |
2016-01-19 |
Redwood Bioscience, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
TW201100104A
(en)
|
2009-03-27 |
2011-01-01 |
Glaxo Group Ltd |
Drug fusions and conjugates
|
US9173891B2
(en)
|
2009-04-20 |
2015-11-03 |
Angiochem, Inc. |
Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
|
IN2012DN00248A
(en)
|
2009-07-02 |
2015-05-01 |
Angiochem Inc |
|
US9663778B2
(en)
|
2009-07-09 |
2017-05-30 |
OPKO Biologies Ltd. |
Long-acting coagulation factors and methods of producing same
|
CN102612376A
(en)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
Growth hormones with prolonged in-vivo efficacy
|
SG10201407329RA
(en)
|
2009-08-14 |
2015-01-29 |
Phasebio Pharmaceuticals Inc |
Modified vasoactive intestinal peptides
|
CN101993485B
(en)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
|
CN101993496B
(en)
*
|
2009-08-20 |
2013-06-05 |
重庆富进生物医药有限公司 |
Dual blood sugar and blood fat adjusting fusion protein and preparation method and application thereof
|
US20120276098A1
(en)
|
2009-09-30 |
2012-11-01 |
Bruce Hamilton |
Drug fusions and conjugates with extended half life
|
WO2011043530A1
(en)
*
|
2009-10-09 |
2011-04-14 |
(주)알테오젠 |
Glp-1 analog fusions, and composition for preventing or treating diabetes containing the fusions as an active ingredient
|
US8697648B2
(en)
|
2009-10-20 |
2014-04-15 |
Georgia State University Research Foundation, Inc. |
Protein agent for diabetes treatment and β cell imaging
|
RU2607374C2
(en)
|
2009-10-30 |
2017-01-10 |
Новозаймс Байофарма Дк А/С |
Versions of albumin
|
CN102070717B
(en)
*
|
2009-11-19 |
2013-04-10 |
东莞太力生物工程有限公司 |
Fusion protein, preparation method thereof, DNA sequence for coding protein, expression vector, host cell and protein-containing medicinal compoisition
|
EA024441B1
(en)
|
2009-12-08 |
2016-09-30 |
Тева Фармасьютикал Индастриз Лтд. |
BChE-ALBUMIN FUSION PROTEIN FOR THE TREATMENT OF COCAINE ABUSE
|
SI2525834T1
(en)
|
2010-01-22 |
2019-10-30 |
Novo Nordisk Healthcare Ag |
Growth hormones with prolonged in-vivo efficacy
|
EP2525833A2
(en)
|
2010-01-22 |
2012-11-28 |
Novo Nordisk Health Care AG |
Stable growth hormone compounds
|
US9981017B2
(en)
|
2010-04-02 |
2018-05-29 |
Hanmi Science Co., Ltd. |
Insulin conjugate using an immunoglobulin fragment
|
AR081066A1
(en)
|
2010-04-02 |
2012-06-06 |
Hanmi Holdings Co Ltd |
INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
|
WO2011124718A1
(en)
|
2010-04-09 |
2011-10-13 |
Novozymes A/S |
Albumin derivatives and variants
|
CN101875700B
(en)
*
|
2010-04-09 |
2012-09-26 |
无锡和邦生物科技有限公司 |
Method for improving bioactivity of exendin fusion protein
|
WO2011123943A1
(en)
|
2010-04-09 |
2011-10-13 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
RU2012151296A
(en)
|
2010-04-30 |
2014-06-10 |
Санва Кагаку Кенкюсо Ко., Лтд |
A PEPTIDE FOR IMPROVING THE BIO-STABILITY OF A BIOACTIVE SUBSTANCE AND A BIOACTIVE SUBSTANCE HAVING AN INCREASED BIO-STABILITY
|
EP2566502A4
(en)
|
2010-05-04 |
2013-10-09 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
WO2011153642A1
(en)
*
|
2010-06-10 |
2011-12-15 |
Angiochem Inc. |
Leptin and leptin analog conjugates and fusion proteins and uses thereof
|
CN101891823B
(en)
*
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
Exendin-4 and analog fusion protein thereof
|
WO2011162830A2
(en)
*
|
2010-06-24 |
2011-12-29 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
CN103080125A
(en)
|
2010-07-02 |
2013-05-01 |
安吉奥开米公司 |
Short and D-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
|
CN102311501A
(en)
*
|
2010-07-08 |
2012-01-11 |
天津药物研究院 |
Fusion protein comprising GLP-1 (Glucagon-Like Peptide) or analog thereof and preparation method as well as application thereof
|
CN101906158B
(en)
*
|
2010-07-14 |
2013-10-23 |
中国药科大学 |
Pegylation hypoglycemic polypeptide and preparation method and application thereof
|
KR101382593B1
(en)
|
2010-07-21 |
2014-04-10 |
한미사이언스 주식회사 |
Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
|
CN102532323B
(en)
*
|
2010-12-09 |
2014-07-23 |
天津药物研究院 |
Polypeptide complex, pharmaceutical composition, as well as preparation method and application of polypeptide complex
|
PT2651398T
(en)
|
2010-12-16 |
2018-03-09 |
Novo Nordisk As |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
CN102533655A
(en)
*
|
2010-12-21 |
2012-07-04 |
青岛黄海制药有限责任公司 |
CHO-S cell strain for efficient expression type human recombinant protein GLP1/Fc and establishment method thereof
|
EP2658979B1
(en)
*
|
2010-12-27 |
2018-02-14 |
Alexion Pharmaceuticals, Inc. |
Compositions comprising natriuretic peptides and methods of use thereof
|
EP2663647A4
(en)
|
2011-01-14 |
2015-08-19 |
Redwood Bioscience Inc |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
JP5948683B2
(en)
|
2011-02-28 |
2016-07-06 |
国立研究開発法人国立循環器病研究センター |
Medicament for inhibiting malignant tumor metastasis
|
CA2828811C
(en)
|
2011-03-03 |
2021-09-21 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
EP2696687B1
(en)
|
2011-04-12 |
2016-10-26 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
US9561262B2
(en)
|
2011-06-06 |
2017-02-07 |
Phasebio Pharmaceuticals, Inc. |
Use of modified vasoactive intestinal peptides in the treatment of hypertension
|
IN2013MN02441A
(en)
|
2011-06-28 |
2015-06-12 |
Inhibrx Llc |
|
US10400029B2
(en)
|
2011-06-28 |
2019-09-03 |
Inhibrx, Lp |
Serpin fusion polypeptides and methods of use thereof
|
KR20140068861A
(en)
*
|
2011-06-28 |
2014-06-09 |
인히브릭스 엘엘씨 |
Wap domain fusion polypeptides and methods of use thereof
|
JP2014522641A
(en)
|
2011-07-01 |
2014-09-08 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Relaxin fusion polypeptides and uses thereof
|
MX2014000316A
(en)
|
2011-07-08 |
2014-02-19 |
Bayer Ip Gmbh |
Fusion proteins releasing relaxin and uses thereof.
|
CN103764165A
(en)
|
2011-08-19 |
2014-04-30 |
独立行政法人国立循环器病研究中心 |
Drug for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A agonist and GC-B agonist
|
EP2749883A4
(en)
*
|
2011-08-25 |
2015-05-27 |
Lsi Medience Corp |
Method for determining glucagon-like peptide-1, and kit for use in said method
|
US9758560B2
(en)
|
2011-09-06 |
2017-09-12 |
Novo Nordisk A/S |
GLP-1 derivatives
|
KR20130049671A
(en)
|
2011-11-04 |
2013-05-14 |
한미사이언스 주식회사 |
Method for preparation of biological active polypeptide conjugate
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
JP2015500823A
(en)
|
2011-12-09 |
2015-01-08 |
ノヴォ ノルディスク アー/エス |
GLP-1 agonist
|
KR101895047B1
(en)
|
2011-12-30 |
2018-09-06 |
한미사이언스 주식회사 |
A site-specific GLP-2 conjugate using an immunoglobulin fragment
|
CN104204218A
(en)
|
2012-01-26 |
2014-12-10 |
安姆根有限公司 |
Growth differentiation factor 15 (GDF-15) polypeptides
|
AR090281A1
(en)
|
2012-03-08 |
2014-10-29 |
Hanmi Science Co Ltd |
IMPROVED PROCESS FOR THE PREPARATION OF A PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEX
|
PL2825556T3
(en)
|
2012-03-16 |
2018-10-31 |
Albumedix A/S |
Albumin variants
|
HUE062740T2
(en)
|
2012-03-22 |
2023-12-28 |
Novo Nordisk As |
Compositions of glp-1 peptides and preparation thereof
|
PT2827845T
(en)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Compositions comprising a delivery agent and preparation thereof
|
MY167814A
(en)
|
2012-04-19 |
2018-09-26 |
Opko Biologics Ltd |
Long-acting oxyntomodulin variants and methods of producing same
|
RU2014150850A
(en)
|
2012-05-16 |
2016-07-10 |
Глэксо Груп Лимитед |
LOAD-LOADED POLYEPEPTIDE DEW NANOPARTICLES FOR ORAL ADMINISTRATION
|
AU2013263349B2
(en)
|
2012-05-17 |
2016-09-08 |
Extend Biosciences, Inc |
Carriers for improved drug delivery
|
CN112142855A
(en)
*
|
2012-05-18 |
2020-12-29 |
爱德迪安(北京)生物技术有限公司 |
Protein for diabetes treatment, protein conjugate and application thereof
|
US10052366B2
(en)
|
2012-05-21 |
2018-08-21 |
Alexion Pharmaceuticsl, Inc. |
Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
|
TR201808753T4
(en)
|
2012-06-08 |
2018-07-23 |
Alkermes Pharma Ireland Ltd |
Ligands modified by circular permutations as agonists and antagonists.
|
JP6517690B2
(en)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー/エス |
Tablet formulation containing peptide and delivery agent
|
CA2878640C
(en)
|
2012-07-13 |
2023-10-24 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
AR091902A1
(en)
*
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
LIQUID FORMULATION OF A PROLONGED INSULIN CONJUGATE
|
AR092862A1
(en)
*
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
LIQUID FORMULATION OF PROLONGED ACTION INSULIN AND AN INSULINOTROPIC PEPTIDE AND PREPARATION METHOD
|
AR094821A1
(en)
*
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
LIQUID FORMULATION OF AN INSULINOTROPIC PEPTIDE CONJUGATE OF PROLONGED ACTION
|
UA116217C2
(en)
|
2012-10-09 |
2018-02-26 |
Санофі |
Exendin-4 derivatives as dual glp1/glucagon agonists
|
CA2890766A1
(en)
|
2012-11-08 |
2014-05-15 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
BR122020018510B1
(en)
|
2012-11-20 |
2023-03-14 |
Opko Biologics Ltd |
METHOD FOR INCREMENTALLY INCREASE THE HYDRODYNAMIC SIZE OF AN ACTIVATED COAGULATION FACTOR VIIA
|
WO2014089354A1
(en)
|
2012-12-07 |
2014-06-12 |
The Regents Of The University Of California |
Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
MA38276B1
(en)
|
2012-12-21 |
2018-03-30 |
Sanofi Sa |
Derivatives of exendin 4 for use in the treatment of metabolic syndrome disorders, including diabetes and obesity, as well as the reduction of excessive dietary intake.
|
CA2896793A1
(en)
|
2013-01-15 |
2014-07-24 |
Teva Pharmaceutical Industries Ltd. |
Formulations of albu-bche, preparation and uses thereof
|
US9546203B2
(en)
*
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
JP6464145B2
(en)
|
2013-04-05 |
2019-02-06 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
Growth hormone compound preparation
|
US10093745B2
(en)
|
2013-05-29 |
2018-10-09 |
The Regents Of The University Of California |
Anti-CSPG4 fusions with interferon for the treatment of malignancy
|
CN104277112B
(en)
|
2013-07-04 |
2018-01-26 |
嘉和生物药业有限公司 |
Long-acting hypoglycemic fusion protein
|
MA38873B1
(en)
*
|
2013-07-31 |
2018-11-30 |
Amgen Inc |
Constructs containing growth differentiation factor 15 (gdf-15)
|
CN103408669B
(en)
*
|
2013-08-01 |
2016-01-20 |
江苏泰康生物医药有限公司 |
GLP-1 analog fusion, and its production and use
|
CN104371019B
(en)
|
2013-08-13 |
2019-09-10 |
鸿运华宁(杭州)生物医药有限公司 |
It is a kind of can with GLP-1R specifically bind antibody and its with the fused protein of GLP-1
|
EP3033355A1
(en)
*
|
2013-08-16 |
2016-06-22 |
Medimmune Limited |
Gip and glp-1 receptor dual-agonists for the treatment of diabetes
|
CA2926087C
(en)
|
2013-10-10 |
2023-03-14 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
US20150158926A1
(en)
|
2013-10-21 |
2015-06-11 |
Opko Biologics, Ltd. |
Long-acting polypeptides and methods of producing and administering same
|
WO2015086548A1
(en)
*
|
2013-12-10 |
2015-06-18 |
F. Hoffmann-La Roche Ag |
Use of the binding domain of a subunit of a multi-subunit structure for targeted delivery of pharmaceutically active entities to the multi-subunit structure
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
WO2015086730A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
EP3080149A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
MY192248A
(en)
*
|
2014-03-31 |
2022-08-10 |
Hanmi Pharm Ind Co Ltd |
Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
|
TW201625668A
(en)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
|
TW201625670A
(en)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
|
TW201625669A
(en)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
|
WO2015165480A1
(en)
|
2014-04-30 |
2015-11-05 |
Institute For Research In Biomedicine |
Human cytomegalovirus vaccine compositions and method of producing the same
|
NO2776305T3
(en)
|
2014-04-23 |
2018-01-27 |
|
|
US11052132B2
(en)
|
2014-05-08 |
2021-07-06 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
WO2016007873A1
(en)
|
2014-07-11 |
2016-01-14 |
The Regents Of The University Of Michigan |
Compositions and methods for treating craniosynostosis
|
CN104558198A
(en)
*
|
2014-07-25 |
2015-04-29 |
成都贝爱特生物科技有限公司 |
Preparation method and application of fusion protein of GLP-1 analogue and amylin analogue
|
CN104257696B
(en)
*
|
2014-09-04 |
2017-08-25 |
西安国誉生物科技有限公司 |
A kind of steady sugar yeast bacterium powder of hypoglycemic and its preparation method and application
|
EP3189072B1
(en)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Gip peptide analogues
|
WO2016055610A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Novo Nordisk A/S |
Stable glp-1 based glp-1/glucagon receptor co-agonists
|
CN104327187B
(en)
*
|
2014-10-11 |
2018-06-08 |
上海兴迪金生物技术有限公司 |
A kind of recombined human GLP-1-Fc fusion proteins
|
WO2016065052A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Insulin vitamin d conjugates
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
JP6946182B2
(en)
|
2014-10-22 |
2021-10-06 |
エクステンド バイオサイエンシズ インコーポレーテッドExtend Biosciences, Inc |
Therapeutic Vitamin D Conjugate
|
AU2015343048A1
(en)
*
|
2014-11-06 |
2017-05-18 |
Children's Research Institute, Children's National Medical Center |
Immunotherapeutics for cancer and autoimmune diseases
|
JP6787894B2
(en)
|
2014-12-05 |
2020-11-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
Treatment of seizures with recombinant alkaline phosphatase
|
CA2968987C
(en)
*
|
2014-12-08 |
2022-05-10 |
1Globe Biomedical Co., Ltd. |
Soluble universal adcc-enhancing synthetic fusion gene and peptide technology and its use thereof
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
AU2016211447B2
(en)
|
2015-01-28 |
2021-09-23 |
Alexion Pharmaceuticals, Inc. |
Methods of treating a subject with an alkaline phosphatase deficiency
|
CN114652817A
(en)
|
2015-02-09 |
2022-06-24 |
费斯生物制药公司 |
Methods and compositions for treating muscle diseases and disorders
|
WO2016127887A1
(en)
|
2015-02-11 |
2016-08-18 |
杭州鸿运华宁生物医药工程有限公司 |
Stabilized solution preparation of pharmaceutical glp-1r antibody fusion protein
|
EA201792084A8
(en)
*
|
2015-04-01 |
2019-06-28 |
Зе Скриппс Рисёрч Инститьют |
METHODS AND COMPOSITIONS RELATED TO POLYPEPTIDES - GPCR AGONISTS
|
UA126270C2
(en)
|
2015-04-10 |
2022-09-14 |
Емджен Інк. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
AR105616A1
(en)
|
2015-05-07 |
2017-10-25 |
Lilly Co Eli |
FUSION PROTEINS
|
AR105319A1
(en)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
|
EP3307326B9
(en)
|
2015-06-15 |
2021-02-24 |
Angiochem Inc. |
Methods for the treatment of leptomeningeal carcinomatosis
|
ES2893616T3
(en)
|
2015-06-19 |
2022-02-09 |
Opko Biologics Ltd |
Long-acting coagulation factors and methods for their production
|
AR105284A1
(en)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
|
KR102644116B1
(en)
|
2015-08-17 |
2024-03-05 |
알렉시온 파마슈티칼스, 인코포레이티드 |
Preparation of alkaline phosphatase
|
CA2989966C
(en)
|
2015-08-20 |
2024-04-30 |
Albumedix A/S |
Albumin variants and conjugates
|
WO2017041001A2
(en)
|
2015-09-04 |
2017-03-09 |
The California Institute For Biomedical Research |
Insulin immunoglobulin fusion proteins
|
EP3355904A4
(en)
|
2015-09-28 |
2019-06-12 |
Alexion Pharmaceuticals, Inc. |
Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
|
EP3368062A4
(en)
|
2015-10-30 |
2019-07-03 |
Alexion Pharmaceuticals, Inc. |
Methods for treating craniosynostosis in a patient
|
CN105367664B
(en)
*
|
2015-11-04 |
2019-09-20 |
成都贝爱特生物科技有限公司 |
Activate GLP-1 receptor and the preparation of the fusion protein of the difunctional effect of Amylin receptor and application thereof
|
EP3960760A1
(en)
*
|
2015-11-16 |
2022-03-02 |
Ubiprotein, Corp. |
A method for extending half-life of a protein
|
BR112018010535A2
(en)
|
2015-11-24 |
2018-11-13 |
Transfert Plus Sec |
peptide compounds and peptide conjugates for the treatment of cancer by receptor-mediated chemotherapy
|
EP3426286A4
(en)
|
2016-03-08 |
2019-12-04 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in children
|
EP3436020A4
(en)
|
2016-04-01 |
2019-12-25 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia in adolescents and adults
|
MX2018011833A
(en)
|
2016-04-01 |
2019-02-13 |
Alexion Pharma Inc |
Treating muscle weakness with alkaline phosphatases.
|
CA3019398A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
US10988744B2
(en)
|
2016-06-06 |
2021-04-27 |
Alexion Pharmaceuticals, Inc. |
Method of producing alkaline phosphatase
|
AU2017296352A1
(en)
|
2016-07-11 |
2019-02-21 |
Opko Biologics Ltd. |
Long-acting coagulation factor VII and methods of producing same
|
CN106046176B
(en)
|
2016-08-16 |
2019-09-10 |
中国药科大学 |
A kind of high active long-acting hypoglycemic fusion protein and preparation method thereof and medical usage
|
US11116821B2
(en)
|
2016-08-18 |
2021-09-14 |
Alexion Pharmaceuticals, Inc. |
Methods for treating tracheobronchomalacia
|
WO2018045872A1
(en)
*
|
2016-09-06 |
2018-03-15 |
中国药科大学 |
Polypeptide and uses thereof
|
CN106279400A
(en)
*
|
2016-09-06 |
2017-01-04 |
中国药科大学 |
Design of P8 incretin peptide and application thereof
|
CN109200273B
(en)
*
|
2017-07-04 |
2021-02-19 |
中国药科大学 |
Application of polypeptide in preparation of medicine for preventing or treating fatty liver disease
|
CN110582302A
(en)
*
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
Compositions and methods for nucleic acid and/or protein payload delivery
|
CN106519016A
(en)
*
|
2016-12-20 |
2017-03-22 |
中国药科大学 |
Design and application of blood glucose reducing and lipid regulating peptide Progly
|
CN107033234B
(en)
*
|
2017-01-03 |
2018-06-26 |
北京凯因科技股份有限公司 |
Acylated glp-1 derivatives
|
WO2018138170A1
(en)
|
2017-01-25 |
2018-08-02 |
Medimmune, Llc |
Relaxin fusion polypeptides and uses thereof
|
AU2018243320A1
(en)
|
2017-03-31 |
2019-10-10 |
Alexion Pharmaceuticals, Inc. |
Methods for treating hypophosphatasia (HPP) in adults and adolescents
|
CN108727486A
(en)
*
|
2017-04-24 |
2018-11-02 |
舒泰神(北京)生物制药股份有限公司 |
Long-acting nerve growth factor, preparation method and combinations thereof
|
WO2018213928A1
(en)
|
2017-05-24 |
2018-11-29 |
Transfert Plus, S.E.C. |
Peptide compounds, conjugate compounds and uses thereof for treating inflammatory diseases
|
JP2020521784A
(en)
|
2017-05-31 |
2020-07-27 |
ユニバーシティ オブ コペンハーゲン |
Long-acting GIP peptide analogues
|
PL3474820T3
(en)
|
2017-08-24 |
2024-05-13 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
WO2019067499A1
(en)
|
2017-09-27 |
2019-04-04 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-cd200 therapy
|
CA3082625A1
(en)
|
2017-11-21 |
2019-05-31 |
Eli Lilly And Company |
Methods of using and compositions containing dulaglutide
|
CN109836504B
(en)
*
|
2017-11-24 |
2022-08-02 |
浙江道尔生物科技有限公司 |
Multi-domain active protein for treating metabolic diseases
|
CN116143939A
(en)
*
|
2017-11-24 |
2023-05-23 |
浙江道尔生物科技有限公司 |
Multiple active protein for treating metabolic diseases
|
WO2019119673A1
(en)
|
2017-12-19 |
2019-06-27 |
北京吉源生物科技有限公司 |
Double gene-modified stem cell and use thereof
|
CN113603794B
(en)
*
|
2018-01-11 |
2024-01-16 |
安源医药科技(上海)有限公司 |
Synergistic bifunctional proteins for regulating blood glucose and lipids
|
WO2019140021A1
(en)
|
2018-01-12 |
2019-07-18 |
Eli Lilly And Company |
Combination therapy
|
CN110092835A
(en)
*
|
2018-01-30 |
2019-08-06 |
上海惠盾生物技术有限公司 |
A kind of GLP-1 analog-COL3A1 fusion protein
|
BR112020014624A2
(en)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT)
|
WO2019190752A1
(en)
|
2018-03-30 |
2019-10-03 |
Alexion Pharmaceuticals, Inc. |
Manufacturing of glycoproteins
|
HUE060135T2
(en)
|
2018-04-05 |
2023-02-28 |
Sun Pharmaceutical Ind Ltd |
Novel glp-1 analogues
|
PE20201350A1
(en)
|
2018-04-09 |
2020-11-30 |
Amgen Inc |
FUSION PROTEINS OF THE GROWTH DIFFERENTIATION FACTOR 15
|
WO2019200594A1
(en)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
Acylated glp-1 derivative
|
CN110964116A
(en)
*
|
2018-09-26 |
2020-04-07 |
北京辅仁瑞辉生物医药研究院有限公司 |
GLP1-Fc fusion proteins and conjugates thereof
|
MX2021004665A
(en)
*
|
2018-10-22 |
2021-08-24 |
Janssen Pharmaceutica Nv |
Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof.
|
EP3891173A1
(en)
|
2018-12-03 |
2021-10-13 |
Antag Therapeutics ApS |
Modified gip peptide analogues
|
WO2020118843A1
(en)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
Glp-1 mutant, preparation method and application thereof
|
CA3123979A1
(en)
|
2018-12-21 |
2020-06-25 |
Jiangsu Hengrui Medicine Co., Ltd. |
Bispecific protein
|
CA3056663C
(en)
|
2019-04-05 |
2022-10-18 |
Jeffrey S. RIESMEYER |
Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
|
CN110151980B
(en)
*
|
2019-06-30 |
2022-12-09 |
中国药科大学 |
Application of GLP-1 receptor agonist fusion protein in preparation of medicine for preventing or treating hyperlipidemia
|
EP4106724A1
(en)
|
2020-02-18 |
2022-12-28 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
AU2021224412A1
(en)
|
2020-02-22 |
2022-09-15 |
Jcr Pharmaceuticals Co., Ltd. |
Human transferrin receptor binding peptide
|
CN115925994B
(en)
*
|
2020-09-30 |
2023-09-22 |
北京质肽生物医药科技有限公司 |
Polypeptide conjugates and methods of use
|
EP4317174A1
(en)
|
2021-03-22 |
2024-02-07 |
Peptiaid Inc |
Peptide and peptide-containing composition
|
TW202305012A
(en)
|
2021-03-22 |
2023-02-01 |
日商肽夢想股份有限公司 |
c-Met protein-binding peptide complex
|
CN113150172B
(en)
*
|
2021-04-28 |
2023-09-22 |
中国药科大学 |
GLP-1R/GIPR double-target agonist fusion protein and preparation method and application thereof
|
CN117677628A
(en)
|
2021-06-18 |
2024-03-08 |
肽梦想株式会社 |
GHR binding pending peptides and compositions comprising the same
|
WO2023022234A1
(en)
|
2021-08-19 |
2023-02-23 |
ペプチドリーム株式会社 |
Human transferrin receptor–binding peptide
|
WO2023026994A1
(en)
|
2021-08-21 |
2023-03-02 |
武田薬品工業株式会社 |
Human transferrin receptor binding peptide-drug conjugate
|
CA3229962A1
(en)
|
2021-08-24 |
2023-03-02 |
Peptidream Inc. |
Human transferrin receptor-binding antibody-peptide conjugate
|
AU2022355276A1
(en)
|
2021-09-30 |
2024-05-16 |
Peptidream Inc. |
Peptide
|
CN113801853B
(en)
*
|
2021-11-19 |
2022-03-15 |
山东兴瑞生物科技有限公司 |
Exendin-4 fusion gene modified MSC and application thereof
|
CN117241821B
(en)
*
|
2022-03-25 |
2024-04-09 |
北京质肽生物医药科技有限公司 |
Pharmaceutical compositions of polypeptide conjugates and methods of use thereof
|
CN116848243B
(en)
*
|
2022-03-30 |
2024-03-19 |
北京质肽生物医药科技有限公司 |
Liquid pharmaceutical compositions of polypeptide conjugates and methods of use thereof
|
CN114774496B
(en)
*
|
2022-06-21 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
Method for preparing GLP-1 analogue through high-density fermentation
|